en · de · es · pt
melanotan-2-notes.peptides3626.com › News › Background And Chemical Profile — Practical Notes

Background And Chemical Profile — Practical Notes

By Editorial Desk · published 2025-10-08 · last reviewed 2025-11-29 · News

Everything below concerns MC1R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Related pages on this site

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Origins and Research Status

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Reference notes

The Socialist Party of Albania (Albanian: Partia Socialiste e Shqipërisë, PSSh), also known as simply the Socialist Party (Albanian: Partia Socialiste, PS), is a social-democratic centre-left political party in Albania. It is the successor to the Party of Labour of Albania, which reconstituted itself under its current name on 13 June 1991 after the fall of communism in an effort to adapt to the new political landscape. It has been the country’s Governing Party since 2013. The Socialist Party is one of the two major parties in Albanian politics along with the Democratic Party. The PS is an associate of the Party of European Socialists and a member of the Socialist International.

=== Liver transplant === In people who develop acute liver failure or who are otherwise expected to die from liver failure, the mainstay of management is liver transplantation. Liver transplants are performed in specialist centers. The most commonly used criteria for liver transplant were developed by physicians at King's College Hospital in London. Patients are recommended for transplant if they have an arterial blood pH less than 7.3 after fluid resuscitation or if a patient has Grade III or IV encephalopathy, a prothrombin time greater than 100 seconds, and a serum creatinine greater than 300 mmol/L In a 24-hour period. Other forms of liver support have been used including partial liver transplants. These techniques have the advantage of supporting the patient while their own liver regenerates. Once liver function returns immunosuppressive drugs are commenced and they have to take immunosuppressive medication for the rest of their lives.

=== GABAB receptor agonists === The GABAB receptor agonist sodium oxybate (SXB; Xyrem), also known as γ-hydroxybutyrate (GHB), has hypnotic and sleep-improving effects. It robustly increases slow wave sleep (deep sleep), decreases sleep fragmentation, and improves rapid eye movement (REM) sleep consolidation, all whilst preserving physiological sleep architecture. The drug is approved and clinically used in the treatment of narcolepsy and excessive daytime sleepiness (EDS). Narcolepsy is associated with poor sleep, and sodium oxybate improves sleep quality and stability in the condition, in turn reducing symptoms like daytime sleepiness and cataplexy. The robust enhancement of slow wave sleep by sodium oxybate is unusual and potentially advantageous relative to other hypnotics. In addition, unlike the case of many other hypnotics, tolerance does not appear to develop to the hypnotic effects of sodium oxybate. Sodium oxybate also completed formal clinical development for fibromyalgia. This condition has very high rates of non-restorative sleep (unrefreshing sleep) that may be directly involved in its symptoms. Sodium oxybate improved sleep in fibromyalgia and showed moderate effectiveness in treating multiple symptoms across the condition including pain and fatigue. However, despite its effectiveness, sodium oxybate was ultimately not approved for treatment of fibromyalgia owing mostly to concerns about possible misuse.

=== Heptapeptide backbone synthesis === The heptapeptide backbone of teicoplanin is assembled by the nonribosomal peptide synthetases (NRPSs) TeiA, TeiB, TeiC and TeiD. Together these comprise seven modules, each containing a number of domains, with each module responsible for the incorporation of a single amino acid. Modules 1, 4, and 5 activate L-4-Hpg as the aminoacyl-AMP, modules 2 and 6 activate L-Tyr, and modules 3 and 7 activate L-3,5-Dpg. The activated amino acids are covalently bound to the NRPS as thioesters by a phosphopantetheine cofactor, which is attached to the peptidyl carrier protein (PCP) domain. The enzyme bound amino acids are then joined by amide bonds by the action of the condensation (C) domain. The heptapetide of teicoplanin contains 4 D-amino acids, formed by epimerization of the activated L-amino acids. Modules 2, 4 and 5 each contain an epimerization (E) domain which catalyzes this change. Module 1 does not contain an E domain, and epimerization is proposed to be catalysed by the C domain. In all, six of the seven total amino acids of the teicoplanin backbone are composed of nonproteinogenic or modified amino acids. Eleven enzymes are coordinatively induced to produce these six required residues. Teicoplanin contains two chlorinated positions, 2 (3-Cl-Tyr) and 6 (3-Cl-β-Hty). The halogenase Tei8* has been acts to catalyze the halogenation of both tyrosine residues.

Sources: en.wikipedia.org

Notes from published material

=== Initial studies === Due to the remarkable rubber elasticity of resilin, scientists began exploring recombinant versions for a variety of material and medical applications. With the rise in DNA technologies, this field of research has seen a rapid increase in the synthesis of biosynthetic protein polymers that can be tuned to having certain mechanical properties. Thus, this field of research is rather promising and can provide new methods for treating diseases and disorders that affect the population. Recombinant resilin was first studied in 2005 when it was expressed in Escherichia coli from the first exon of the Drosophila melanogaster's CG15920 gene. During its study, pure resilin was synthesized into 20% protein-mass hydrogel and was cross-linked with ruthenium-catalyzed tyrosine in the presence of ultraviolet light. This reaction yielded the product, recombinant resilin (rec1-Resilin). One of the most important aspects of successful rec1-Resilin synthesis is that its mechanical properties match that of the original resilin (native resilin). In the study indicated above, scanning probe microscopy (SPM) and atomic-force microscopy (AFM) were used to investigate the mechanical properties of rec1-Resilin and native resilin. The results of these tests revealed that the resilience of both recombinant and native resilin were relatively similar but can differ in its applications. In this study, rec1-Resilin could be placed into a polymeric scaffold to mimic the extracellular matrix in order to generate a cell and tissue responses.

==== International Baccalaureate ==== The International Baccalaureate (IB) Diploma Magnet Program is a course of study. The mission of the program is to develop inquiring, knowledgeable, and caring young people who help to create a better, more peaceful world through intercultural understanding and respect. The IB program offers many benefits to its participants, such as: higher university and college acceptance rates for IB graduates; increased scholarship and grant opportunities; a college-level academic program that transitions students to university and college standards; and teacher development using IB strategies. Locations:

According to Mathieu Boisvert, nidana 3-10 correlate with the five skandhas. Boisvert notes that while sañña, "perception", is not found in the twelvefold chain, it does play a role in the processes described by the chain, particularly between feeling and the arising of samskaras. Likewise, Waldron notes that the anusaya, "underlying tendencies, are the link between the cognitive processes of phassa ("contact") and vedana (feeling), and the afflictive responses of tanha ("craving") and upadana ("grasping").

== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.

alpha-decay -> strong interaction, beta-decay -> weak interaction, gamma-decay -> electromagnetism. In alpha decay, a particle containing two protons and two neutrons, equivalent to a He nucleus, breaks out of the parent nucleus. The process represents a competition between the electromagnetic repulsion between the protons in the nucleus and attractive nuclear force, a residual of the strong interaction. The alpha particle is an especially strongly bound nucleus, helping it win the competition more often. However some nuclei break up or fission into larger particles and artificial nuclei decay with the emission of single protons, double protons, and other combinations. Beta decay transforms a neutron into proton or vice versa. When a neutron inside a parent nuclide decays to a proton, an electron, an anti-neutrino, and nuclide with higher atomic number results. When a proton in a parent nuclide transforms to a neutron, a positron, a neutrino, and nuclide with a lower atomic number results. These changes are a direct manifestation of the weak interaction. Gamma decay resembles other kinds of electromagnetic emission: it corresponds to transitions between an excited quantum state and lower energy state. Any of the particle decay mechanisms often leave the daughter in an excited state, which then decays via gamma emission. Other forms of decay include neutron emission, electron capture, internal conversion, cluster decay.

Sources: en.wikipedia.org

Further detail

=== 2020 sesame seeds contamination === In September 2020, high levels of pesticides were found in 268 tonnes of sesame seeds from India. The contamination had a level of 1000 to 3500 times the limit of 0.05 milligrams per kilogram for ethylene oxide allowed in Europe. This pesticide is forbidden in Europe, where it is recognized to be carcinogenic and mutagenic. A product recall was made, half of the products had an organic certification. In September, alert was raised by Belgium by RASFF, but the product has also been sold in other EU single market countries such as France and Ireland.

Has written for The Guardian London Review of Books, Red Pepper (magazine), Novara Media, Radical Philosophy, and has worked with Jews for Justice for Palestinians, Independent Jewish Voices and Faculty for Israeli–Palestinian Peace (FFIPP) engaged in efforts to end the Israeli occupation of Palestinian land and create a just peace between Israel and Palestine. Anthony Seldon (born 2 August 1953); educator, contemporary historian, journalist, broadcaster, academic, author, wrote biographies of British Prime Ministers, John Major, Tony Blair, Gordon Brown, David Cameron, Theresa May and Boris Johnson; was master (headmaster) of Wellington College, one of Britain's co-educational independent boarding schools, and is current Head Master of Epsom College; is author or editor of more than 45 books on contemporary history, politics and education; was co-founder and first director of Centre for Contemporary British History; co-founder of Action for Happiness, is a governor of the Royal Shakespeare Company, and is on board of a number of charities and educational bodies; is honorary historical adviser to 10 Downing Street and member of the First World War Centenary Culture Committee; was knighted in the 2014 Birthday Honours for services to education and modern political history.

=== Rotator cuff disease === A 2022 review and meta-analysis showed improved patient-rated outcomes in patients with partial rotator cuff tears. At 8 weeks post injection, they found PRP to be effective. A 2021 prospective study examined the effectiveness of PRP for partial thickness rotator cuff tears. Patients were given 2 separate PRP injections and followed for 2 years. The study noted: "No adverse events were seen in any patient. Based on global rating scores positive results were seen in 77.9 % of patients at 6 months, 71.6 % at 1 year, and 68.8 % of patients at 2 years". They found PRP most effective in more damaged tendons. A 2021 meta-analysis found that PRP was effective for partial rotator cuff tears but the effects were no longer evident at 1 year. PRP has been shown to be superior to cortisone injections in several studies. This is especially evident in the longer term. A 2019 review found it not to be useful in rotator cuff disease. A 2018 review found that it may be useful. A 2009 review found few randomized controlled trials that adequately evaluated the safety and efficacy of PRP treatments and concluded that PRP was "a promising, but not proven, treatment option for joint, tendon, ligament, and muscle injuries".

Fluids cannot generally be pulled, so a vacuum cannot be created by suction. Suction can spread and dilute a vacuum by letting a higher pressure push fluids into it, but the vacuum has to be created first before suction can occur. The easiest way to create an artificial vacuum is to expand the volume of a container. For example, the diaphragm muscle expands the chest cavity, which causes the volume of the lungs to increase. This expansion reduces the pressure and creates a partial vacuum, which is soon filled by air pushed in by atmospheric pressure. To continue evacuating a chamber indefinitely without requiring infinite growth, a compartment of the vacuum can be repeatedly closed off, exhausted, and expanded again. This is the principle behind positive displacement pumps, like the manual water pump for example. Inside the pump, a mechanism expands a small sealed cavity to create a vacuum. Because of the pressure differential, some fluid from the chamber (or the well, in our example) is pushed into the pump's small cavity. The pump's cavity is then sealed from the chamber, opened to the atmosphere, and squeezed back to a minute size.

In the points where the image is present, the discoloration affects only two or three fibers on the topmost part of the threads of the cloth. In each fiber, the yellow discoloration penetrates only for 200 nm in the external cell layer. A fiber is not necessarily colored for all its length, but, in the parts where it is, it has the property of being colored all around its cylindrical surface. Under the crossing threads of the weave, the image is not present. The discoloration seems caused by a kind of dehydrative oxidation process, which has discolored and chemically altered the surfaces of certain surface fibrils. The image of the Shroud is an areal density image, in the sense that the levels of darkness are not given by variations of the color, which instead is approximately constant all over the image, but by a variation of the number of yellowed fibers per unit area. Therefore, it can be considered a halftone image. Furthermore, there is no difference in terms of distribution of fiber coloration and maximum densities between the front and the rear of the image. While the blood images could have come from a contact mechanism, the body image could not. The mapping between body-only image densities and expected cloth–body distances is not consistent with the image having been formed by direct contact with a body, as it is present even when it does not seem possible for the cloth to be in contact with the body.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

Network